Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors

Oric Pharmaceuticals Inc ORIC has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in advanced solid tumors.
Data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
As of the database cutoff date of April 21, the recommended dose of 160 mg of ORIC-101 was well-tolerated.
Treatment-related adverse events were primarily mild or moderate, with only three severe events reported, all of which resolved with dose interruption.
There were no treatment-related discontinuations and no requirement for prophylactic G-CSF at the RP2D.
Five partial responses were observed, including one confirmed and four unconfirmed.
Further evidence of antitumor activity was demonstrated by prolonged disease stabilization across multiple solid tumors.
Notably, three of the four efficacy evaluable patients with relapsed pancreatic ductal adenocarcinoma demonstrated extended progression-free survival ranging from 3.6 months to 5.3+ months in the third-line or later setting, despite having already previously progressed on nab-paclitaxel.
Enrollment in the expansion cohorts is ongoing, and updated data from the Phase 1b trial is expected in 2022.
ORIC-101 is also being evaluated in a Phase 1b trial in combination with Xtandi (enzalutamide) in metastatic prostate cancer.
Initial interim safety, efficacy, and translational data are expected in the second half of 2021.
Price Action: ORIC shares closed at $21.5 on Wednesday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga